West Pharmaceutical Services raised 2026 revenue guidance to $3.41 to $3.42 billion and adjusted EPS guidance to $9.38 to $9.48, after Q3 revenue of $874 million and adjusted EPS of $2.66.
WST · West Pharmaceutical Services Inc · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
West Pharmaceutical Services Inc reported nine-month 2026 net sales of $2,591.7 million, up 14.2%, and operating profit of $623.6 million, up 45.6%; Proprietary Products drove growth, while West Vantage organic sales declined 0.2%.
West Pharmaceutical Services, Inc. reported third-quarter net sales of $874.5 million, up 8.7%, and adjusted-diluted EPS of $2.66, up 35.7%. It raised full-year 2026 net sales guidance to $3.41 billion to $3.42 billion and adjusted-diluted EPS guidance to $9.38 to $9.48.
West Pharmaceutical Services, Inc. entered a five-year credit agreement on October 26, 2026, providing a $750 million revolver and $200 million term loan, and repaid $130.0 million under its existing agreement without early termination penalties.